Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2927 Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies

Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Barriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A,

Keywords: goblet cell adenocarcinomas, chemotherapy, anti-egfr,

#2224 Neuroendocrine Tumours in Tailgut Cysts: A Report of 3 Cases and Review of Literature

Introduction: Retrorectal neuroendocrine tumors (NETs) are rare low grade tumors and their presence in tailgut cyst is rarer.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Pande P

Authors: Pande P, D G, Shah R, Palepu J,

Keywords: presacral neuroendocrine tumours, tailgut cyst, modified Kraske’s approach,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#1892 Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas

Introduction: Neuroendocrine carcinomas (NECs) may arise from any organ system, exhibit various degree of differentiation and have Ki67 indices ranging from 21-100%. After first-line platin based chemotherapy, no standard treatment exists.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Knigge U, Federspiel B, Andreassen M, Kjær A, Langer S,

Keywords: neuroendocrine, neuroendocrine neoplasms, neuroendocrine carcinoma, ngs, genes, mutation, ki67, tp53, kras, braf, pik3a, pten,